IL-28 Elicits Antitumor Responses against

Iwakura, Setsuya Aiba and Mutsuo YamayaSuzuki, Akira Nakamura, Masahiro Okada, Yoichiro Muneo Numasaki, Masatoshi Tagawa, Fumi Iwata, Takashihttp://www.jimmunol.org/content/178/8/5086J Immunol€2007; 178:5086-5098; ;Referenceshttp://www.jimmunol.org/content/178/8/5086.full#ref-list-1This article cites 37 articles, 21 of which you can access for free at: Subscriptionshttp://jimmunol.org/subscriptionsInformation about subscribing to The Journal of Immunology is online at: Permissionshttp://www.aai.org/ji/copyright.htmlSubmit copyright permission requests at: Email Alertshttp://jimmunol.org/cgi/alerts/etocReceive free email-alerts when new articles cite this article. Sign up at:

[1]  Cheng-Wen Wu,et al.  Antitumor and Antimetastatic Activity of IL-231 , 2003, The Journal of Immunology.

[2]  M. Wadhwa,et al.  Biological activity of interleukins-28 and -29: comparison with type I interferons. , 2005, Cytokine.

[3]  J. Norton,et al.  The role of IFN-γ in rejection of established tumors by IL-12: Source of production and target , 2002 .

[4]  Simon C Watkins,et al.  Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. , 1994, Cancer research.

[5]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[6]  M. Lotze,et al.  Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models , 1999, Gene Therapy.

[7]  M. Colombo,et al.  Cytokine gene transduction in the immunotherapy of cancer. , 1997, Advances in pharmacology.

[8]  R. Hawley,et al.  Growth control mechanisms in multiple myeloma. , 1998, Leukemia & lymphoma.

[9]  J. Renauld,et al.  Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. , 2004, The Journal of biological chemistry.

[10]  Scott R. Presnell,et al.  IL-28, IL-29 and their class II cytokine receptor IL-28R , 2002, Nature Immunology.

[11]  I. Frank,et al.  Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients , 1992, The Journal of experimental medicine.

[12]  M. Colombo,et al.  Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15. , 2002, Cancer research.

[13]  S. Brand,et al.  IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[14]  D. Glass,et al.  Cutting Edge: IL-10-Producing CD4+ T Cells Mediate Tumor Rejection1 , 2002, The Journal of Immunology.

[15]  U. Boehm,et al.  Cellular responses to interferon-gamma. , 1997, Annual review of immunology.

[16]  M. Colombo,et al.  Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. , 1992, Cancer research.

[17]  M. Lotze,et al.  IL-17 Enhances the Net Angiogenic Activity and In Vivo Growth of Human Non-Small Cell Lung Cancer in SCID Mice through Promoting CXCR-2-Dependent Angiogenesis1 , 2005, The Journal of Immunology.

[18]  M. Collins,et al.  IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. , 2002, Immunity.

[19]  G. Trinchieri,et al.  Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin‐12) on cell‐mediated cytotoxicity against tumor‐derived and virus‐infected cells , 1993, European journal of immunology.

[20]  T. Schumacher,et al.  Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[21]  M. Lotze,et al.  Interleukin-17 promotes angiogenesis and tumor growth. , 2003, Blood.

[22]  S Pestka,et al.  Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. , 1998, Cancer research.

[23]  Sally R. M. Clarke,et al.  The critical role of CD40/CD40L in the CD4‐dependent generation of CD8+ T cell immunity , 2000, Journal of leukocyte biology.

[24]  M. Colombo,et al.  Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma , 1993, The Journal of experimental medicine.

[25]  E. Tartour,et al.  Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. , 2002, Blood.

[26]  A. Lewis-Antes,et al.  IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex , 2003, Nature Immunology.

[27]  W. Cruikshank,et al.  Cutting Edge: IL-16/CD4 Preferentially Induces Th1 Cell Migration: Requirement of CCR5 1 , 2003, The Journal of Immunology.

[28]  Ying Wang,et al.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 , 2005, Nature Immunology.

[29]  M. Colombo,et al.  Interferon γ–independent Rejection of Interleukin 12–transduced Carcinoma Cells Requires CD4+ T Cells and Granulocyte/Macrophage Colony–stimulating Factor , 1998, The Journal of Experimental Medicine.

[30]  H. Fujiwara,et al.  Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. , 1995, Cancer research.

[31]  D. Taub,et al.  Human Interferon-inducible Protein 10 Is a Potent Inhibitor of Angiogenesis in Vivo , 1995 .

[32]  R. Schreiber,et al.  Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. , 1994, Immunity.

[33]  I. Homma,et al.  Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. , 2002, Immunity.